Patterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study.
10.3857/roj.2013.31.4.177
- Author:
Hyejung CHA
1
;
Jun Won KIM
;
Chang Ok SUH
;
Jin Seok KIM
;
June Won CHEONG
;
Jeongshim LEE
;
Ki Chang KEUM
;
Chang Geol LEE
;
Jaeho CHO
Author Information
1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea. jjhmd@yuhs.ac
- Publication Type:Original Article
- Keywords:
Thyroid neoplasms;
Non-Hodgkin lymphoma;
Physician's practice pattern;
Treatment outcome
- MeSH:
Biopsy;
Diagnosis;
Disease-Free Survival;
Drug Therapy;
Female;
Follow-Up Studies;
Humans;
Lymphoid Tissue;
Lymphoma*;
Lymphoma, B-Cell, Marginal Zone;
Lymphoma, Non-Hodgkin;
Medical Records;
Methods;
Physician's Practice Patterns;
Radiotherapy;
Recurrence;
Retrospective Studies;
Thyroid Gland*;
Thyroid Neoplasms;
Thyroidectomy;
Treatment Outcome
- From:Radiation Oncology Journal
2013;31(4):177-184
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to analyze the patterns of care and treatment outcomes in patients with primary thyroid lymphoma (PTL) in a single institution. MATERIALS AND METHODS: Medical records of 29 patients with PTL treated between April 1994 and February 2012 were retrospectively reviewed. Diagnosis was confirmed by biopsy (n = 17) or thyroidectomy (n = 12). Treatment modality and outcome were analyzed according to lymphoma grade. RESULTS: The median follow-up was 43.2 months (range, 3.8 to 220.8 months). The median age at diagnosis was 57 years (range, 21 to 83 years) and 24 (82.8%) patients were female. Twenty-five (86.2%) patients had PTL with stage IEA and IIEA. There were 8 (27.6%) patients with mucosa-associated lymphoid tissue (MALT) lymphoma and the remaining patients had high-grade lymphoma. Patients were treated with surgery (n = 2), chemotherapy (n = 7), radiotherapy (n = 3) alone, or a combination of these methods (n = 17). Treatment modalities evolved over time and a combination of modalities was preferred, especially for the treatment of high-grade lymphoma in recent years. There was no death or relapse among MALT lymphoma patients. Among high-grade lymphoma patients, 5-year overall survival (OS) and 5-year progression-free survival (PFS) were 75.6% and 73.9%, respectively. Complete remission after initial treatment was the only significant prognostic factor for OS (p = 0.037) and PFS (p = 0.003). CONCLUSION: Patients with PTL showed a favorable outcome, especially with MALT lymphoma. Radiotherapy alone for MALT lymphoma and chemotherapy followed by radiotherapy for high-grade lymphoma can be effective treatment options for PTL.
